Nature, Published online: 01 July 2026; doi:10.1038/s41586-026-10705-2 TROP2 marks poor-prognosis colorectal cancer cells with fetal-like, therapy-resistant states, and therapeutic targeting of TROP2 with antibody–drug conjugates in combination with chemotherapy enhances treatment efficacy by modulating tumour cell plasticity and overcoming resistance.

Source: Nature — Latest Research — read the full report at the original publisher.

This is a curated wire item. The Continuum Brief does not republish full third-party articles; this entry links to the original source.